{"transactions":[{"id":1777031,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-09-19T16:47:30.000Z","date":"2023-09-16","kind":"exercise","planned":false,"acquired":false,"shares":2666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023."}],"balance_after":5334,"derivative":{"underlying":"Common Stock","underlying_shares":2666},"source":{"system":"sec-edgar","filing":"0001209191-23-049977","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1538897/000120919123049977/doc4.xml","form_type":"4"}},{"id":1777030,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-19T16:47:30.000Z","date":"2023-09-16","kind":"exercise","planned":false,"acquired":true,"shares":2666,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."}],"balance_after":3666,"source":{"system":"sec-edgar","filing":"0001209191-23-049977","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1538897/000120919123049977/doc4.xml","form_type":"4"}},{"id":1869147,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-02T16:22:54.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs will vest in their entirety on the earlier to occur of (i) the first anniversary of the date of grant of the award, or (ii) the date of the Company's next Annual Meeting of Stockholders, subject in each case to the director's continued service as a director through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These RSUs will vest in their entirety on the earlier to occur of (i) the first anniversary of the date of grant of the award, or (ii) the date of the Company's next Annual Meeting of Stockholders, subject in each case to the director's continued service as a director through the applicable vesting date."}],"balance_after":4000,"derivative":{"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001209191-23-033715","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1538897/000120919123033715/doc4.xml","form_type":"4"}},{"id":1869146,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T16:22:54.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments of 8.33% of the shares underlying the award until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date."}],"balance_after":6000,"derivative":{"exercise_price":3.7,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-23-033715","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1538897/000120919123033715/doc4.xml","form_type":"4"}},{"id":1880111,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T22:23:41.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":4190,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on May 23, 2023. Price not applicable."}],"balance_after":15095,"source":{"system":"sec-edgar","filing":"0001209191-23-031964","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000120919123031964/doc4.xml","form_type":"4"}},{"id":2127460,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-02T22:42:29.000Z","date":"2022-10-31","kind":"purchase","acquired":true,"shares":3625,"price":86.75,"value":314468.75,"ownership":{"direct":true},"balance_after":10905,"source":{"system":"sec-edgar","filing":"0001567619-22-019081","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922019081/doc1.xml","form_type":"4"}},{"id":2155083,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-09-19T17:08:01.000Z","date":"2022-09-16","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs will vest in three equal annual installments commencing on September 16, 2023. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These RSUs will vest in three equal annual installments commencing on September 16, 2023. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022."}],"balance_after":8000,"derivative":{"underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-22-050549","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1538897/000120919122050549/doc4.xml","form_type":"4"}},{"id":2155082,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-09-19T17:08:01.000Z","date":"2022-09-16","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022."}],"balance_after":12000,"derivative":{"exercise_price":7.349,"expiration_date":"2032-09-15","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-22-050549","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1538897/000120919122050549/doc4.xml","form_type":"4"}},{"id":2180788,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-17T16:32:55.000Z","date":"2022-08-17","kind":"disposition_to_issuer","acquired":false,"shares":209,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."}],"balance_after":0,"derivative":{"exercise_price":65.64,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":209},"source":{"system":"sec-edgar","filing":"0001209191-22-046273","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1538897/000120919122046273/doc4.xml","form_type":"4"}},{"id":2180787,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-17T16:32:55.000Z","date":"2022-08-17","kind":"disposition_to_issuer","acquired":false,"shares":17000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."}],"balance_after":0,"derivative":{"exercise_price":70.6,"expiration_date":"2031-05-23","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-22-046273","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1538897/000120919122046273/doc4.xml","form_type":"4"}},{"id":2180786,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-17T16:32:55.000Z","date":"2022-08-17","kind":"disposition_to_issuer","acquired":false,"shares":2000,"price":76,"value":152000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the \"Issuer\"), Bristol-Myers Squibb Company (\"BMS\") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS (\"Purchaser\"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for $76.00 per Share in cash, without interest, subject to any applicable withholding of taxes (the \"Cash Amount\"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Cash Amount."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-046273","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1538897/000120919122046273/doc4.xml","form_type":"4"}},{"id":2247032,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-02T19:06:18.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date."}],"balance_after":17500,"derivative":{"exercise_price":0.78,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-22-033704","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1538897/000120919122033704/doc4.xml","form_type":"4"}},{"id":2255589,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-27T00:12:25.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":4980,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on May 24, 2022.  Price not applicable."}],"balance_after":7280,"source":{"system":"sec-edgar","filing":"0001567619-22-011784","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922011784/doc1.xml","form_type":"4"}},{"id":2445018,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-05T23:09:39.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on January 3, 2022 represent a pro rata share of the 2021 annual award for independent directors and vest on the date immediately prior to the date of the Company's next regular annual meeting of stockholders, the same vesting date for the 2021 annual award for all other independent directors."}],"balance_after":2300,"source":{"system":"sec-edgar","filing":"0001567619-22-000661","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922000661/doc1.xml","form_type":"4"}},{"id":2660171,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-21T21:14:17.000Z","date":"2021-06-21","kind":"purchase","acquired":true,"shares":2000,"price":81.34,"value":162680.0,"ownership":{"direct":true},"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001209191-21-042325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1538897/000120919121042325/doc4.xml","form_type":"4"}},{"id":2673436,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-10T17:24:59.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date."}],"balance_after":17500,"derivative":{"exercise_price":6.3,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-21-039572","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1538897/000120919121039572/doc4.xml","form_type":"4"}},{"id":2680500,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-04T17:34:51.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the one-year anniversary of the date of grant."}],"balance_after":209,"derivative":{"exercise_price":65.64,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":209},"source":{"system":"sec-edgar","filing":"0001209191-21-038329","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1538897/000120919121038329/doc4.xml","form_type":"4"}},{"id":2694708,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-26T16:50:23.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest in a series of 36 successive equal monthly installments over the three-year period measured from the date of grant."}],"balance_after":17000,"derivative":{"exercise_price":70.6,"expiration_date":"2031-05-23","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-21-035956","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1538897/000120919121035956/doc4.xml","form_type":"4"}},{"id":3112963,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-11T16:51:24.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date."}],"balance_after":17500,"derivative":{"exercise_price":9.17,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-20-035965","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1538897/000120919120035965/doc4.xml","form_type":"4"}},{"id":3150298,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-13T17:05:34.000Z","date":"2020-05-13","kind":"purchase","acquired":true,"shares":10000,"price":8.859,"value":88590.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-20-028871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1538897/000120919120028871/doc4.xml","form_type":"4"}},{"id":3333618,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-12-20T08:14:29.000Z","date":"2019-12-19","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date."}],"balance_after":35000,"derivative":{"exercise_price":6.22,"expiration_date":"2029-12-18","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-19-061430","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1538897/000120919119061430/doc4.xml","form_type":"4"}},{"id":3362229,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":29669,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":114.69,"expiration_date":"2026-08-01","underlying":"Common Stock","underlying_shares":29669},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362228,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":29669,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":104.97,"expiration_date":"2026-05-02","underlying":"Common Stock","underlying_shares":29669},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362227,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":8625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":100.8,"expiration_date":"2026-02-01","underlying":"Common Stock","underlying_shares":8625},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362226,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":8625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":114.08,"expiration_date":"2025-11-09","underlying":"Common Stock","underlying_shares":8625},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362225,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":8625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":132.56,"expiration_date":"2025-07-27","underlying":"Common Stock","underlying_shares":8625},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362224,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":8625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":109.9,"expiration_date":"2025-05-04","underlying":"Common Stock","underlying_shares":8625},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362223,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":10175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":118.57,"expiration_date":"2025-02-02","underlying":"Common Stock","underlying_shares":10175},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362222,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":15670,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":117.18,"expiration_date":"2024-12-19","underlying":"Common Stock","underlying_shares":15670},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362221,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":10175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":103.1,"expiration_date":"2024-10-27","underlying":"Common Stock","underlying_shares":10175},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362220,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":20350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":87.64,"expiration_date":"2024-07-28","underlying":"Common Stock","underlying_shares":20350},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362219,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":17738,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":74.3,"expiration_date":"2024-02-03","underlying":"Common Stock","underlying_shares":17738},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362218,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":19688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":81.56,"expiration_date":"2023-12-02","underlying":"Common Stock","underlying_shares":19688},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362217,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":17738,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":78.12,"expiration_date":"2023-10-28","underlying":"Common Stock","underlying_shares":17738},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362216,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":17738,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":71.33,"expiration_date":"2023-07-29","underlying":"Common Stock","underlying_shares":17738},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362215,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":17738,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":59.24,"expiration_date":"2023-04-29","underlying":"Common Stock","underlying_shares":17738},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362214,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":12488,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":49.48,"expiration_date":"2023-01-28","underlying":"Common Stock","underlying_shares":12488},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362213,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":40.22,"expiration_date":"2022-12-17","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362212,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":8326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":36.68,"expiration_date":"2022-10-31","underlying":"Common Stock","underlying_shares":8326},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362211,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":8326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":34.7,"expiration_date":"2022-07-30","underlying":"Common Stock","underlying_shares":8326},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362210,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":8326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":36.47,"expiration_date":"2022-04-30","underlying":"Common Stock","underlying_shares":8326},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362209,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":10994,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":36.96,"expiration_date":"2022-03-01","underlying":"Common Stock","underlying_shares":10994},"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362208,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Common Stock","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":6252,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"401(k) Plan"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects disposition in connection with the Merger Agreement.  Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362207,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Common Stock","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":366495,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects disposition in connection with the Merger Agreement.  Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362206,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Common Stock","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":74414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS.  These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the \"Effective Time\").  In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights (\"CVRs\") in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":366495,"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362205,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Common Stock","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":45119,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS.  These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the \"Effective Time\").  In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights (\"CVRs\") in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":292081,"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362204,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Common Stock","published_at":"2019-11-22T07:31:34.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":25696,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS.  These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the \"Effective Time\").  In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights (\"CVRs\") in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":246962,"source":{"system":"sec-edgar","filing":"0001415889-19-001379","document":"form4-11222019_071122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001379/form4-11222019_071122.xml","form_type":"4"}},{"id":3362095,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:30.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":115755,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":115755},"source":{"system":"sec-edgar","filing":"0001415889-19-001378","document":"form4-11222019_071117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001378/form4-11222019_071117.xml","form_type":"4"}},{"id":3362094,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Restricted stock Unit","published_at":"2019-11-22T07:31:30.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":18800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":18800},"source":{"system":"sec-edgar","filing":"0001415889-19-001378","document":"form4-11222019_071117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001378/form4-11222019_071117.xml","form_type":"4"}},{"id":3362093,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:30.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":30079,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":30079},"source":{"system":"sec-edgar","filing":"0001415889-19-001378","document":"form4-11222019_071117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001378/form4-11222019_071117.xml","form_type":"4"}},{"id":3362092,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:30.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":17131,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":17131},"source":{"system":"sec-edgar","filing":"0001415889-19-001378","document":"form4-11222019_071117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001378/form4-11222019_071117.xml","form_type":"4"}},{"id":3362091,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:30.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":59234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":71.43,"expiration_date":"2028-10-29","underlying":"Common Stock","underlying_shares":59234},"source":{"system":"sec-edgar","filing":"0001415889-19-001378","document":"form4-11222019_071117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001378/form4-11222019_071117.xml","form_type":"4"}},{"id":3362090,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:30.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":59234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":88.91,"expiration_date":"2028-07-30","underlying":"Common Stock","underlying_shares":59234},"source":{"system":"sec-edgar","filing":"0001415889-19-001378","document":"form4-11222019_071117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001378/form4-11222019_071117.xml","form_type":"4"}},{"id":3362089,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:30.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":59234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":83.13,"expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":59234},"source":{"system":"sec-edgar","filing":"0001415889-19-001378","document":"form4-11222019_071117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001378/form4-11222019_071117.xml","form_type":"4"}},{"id":3362088,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:30.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":33881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":103.26,"expiration_date":"2028-01-29","underlying":"Common Stock","underlying_shares":33881},"source":{"system":"sec-edgar","filing":"0001415889-19-001378","document":"form4-11222019_071117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001378/form4-11222019_071117.xml","form_type":"4"}},{"id":3362087,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:30.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":33881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":100.97,"expiration_date":"2027-10-30","underlying":"Common Stock","underlying_shares":33881},"source":{"system":"sec-edgar","filing":"0001415889-19-001378","document":"form4-11222019_071117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001378/form4-11222019_071117.xml","form_type":"4"}},{"id":3362086,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:30.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":33881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":135.41,"expiration_date":"2027-07-31","underlying":"Common Stock","underlying_shares":33881},"source":{"system":"sec-edgar","filing":"0001415889-19-001378","document":"form4-11222019_071117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001378/form4-11222019_071117.xml","form_type":"4"}},{"id":3362085,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:30.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":33880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":124.06,"expiration_date":"2027-05-01","underlying":"Common Stock","underlying_shares":33880},"source":{"system":"sec-edgar","filing":"0001415889-19-001378","document":"form4-11222019_071117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001378/form4-11222019_071117.xml","form_type":"4"}},{"id":3362084,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:30.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":29669,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":113.18,"expiration_date":"2027-01-30","underlying":"Common Stock","underlying_shares":29669},"source":{"system":"sec-edgar","filing":"0001415889-19-001378","document":"form4-11222019_071117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001378/form4-11222019_071117.xml","form_type":"4"}},{"id":3362083,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:30.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":29669,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":102.18,"expiration_date":"2026-10-31","underlying":"Common Stock","underlying_shares":29669},"source":{"system":"sec-edgar","filing":"0001415889-19-001378","document":"form4-11222019_071117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001378/form4-11222019_071117.xml","form_type":"4"}},{"id":3538571,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Restricted Stock Unit","published_at":"2019-05-06T16:05:31.000Z","date":"2019-05-02","kind":"exercise","acquired":false,"shares":15608,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15608},"source":{"system":"sec-edgar","filing":"0001415889-19-000509","document":"form4-05062019_040519.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919000509/form4-05062019_040519.xml","form_type":"4"}},{"id":3538570,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Common Stock","published_at":"2019-05-06T16:05:31.000Z","date":"2019-05-02","kind":"tax_withholding","acquired":false,"shares":6620,"price":95.21,"value":630290.2,"ownership":{"direct":true},"balance_after":221266,"source":{"system":"sec-edgar","filing":"0001415889-19-000509","document":"form4-05062019_040519.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919000509/form4-05062019_040519.xml","form_type":"4"}},{"id":3538569,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Common Stock","published_at":"2019-05-06T16:05:31.000Z","date":"2019-05-02","kind":"exercise","acquired":true,"shares":15608,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."}],"balance_after":227886,"source":{"system":"sec-edgar","filing":"0001415889-19-000509","document":"form4-05062019_040519.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919000509/form4-05062019_040519.xml","form_type":"4"}},{"id":3616288,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Performance Stock Unit","published_at":"2019-03-05T16:05:41.000Z","date":"2019-03-01","kind":"exercise","acquired":false,"shares":33809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each performance stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The performance stock units granted to the reporting person on January 28, 2019 vested and settled for shares of the Company's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The performance stock units granted to the reporting person on January 28, 2019 vested and settled for shares of the Company's common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":33809},"source":{"system":"sec-edgar","filing":"0001415889-19-000253","document":"form4-03052019_040328.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919000253/form4-03052019_040328.xml","form_type":"4"}},{"id":3616287,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Restricted Stock Unit","published_at":"2019-03-05T16:05:41.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":115755,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020.  Vested shares will be delivered to the reporting person promptly after the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020.  Vested shares will be delivered to the reporting person promptly after the vesting date."}],"balance_after":115755,"derivative":{"underlying":"Common Stock","underlying_shares":115755},"source":{"system":"sec-edgar","filing":"0001415889-19-000253","document":"form4-03052019_040328.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919000253/form4-03052019_040328.xml","form_type":"4"}},{"id":3616286,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Common Stock","published_at":"2019-03-05T16:05:41.000Z","date":"2019-03-01","kind":"tax_withholding","acquired":false,"shares":13900,"price":85.96,"value":1194844.0,"ownership":{"direct":true},"balance_after":212278,"source":{"system":"sec-edgar","filing":"0001415889-19-000253","document":"form4-03052019_040328.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919000253/form4-03052019_040328.xml","form_type":"4"}},{"id":3616285,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Common Stock","published_at":"2019-03-05T16:05:41.000Z","date":"2019-03-01","kind":"exercise","acquired":true,"shares":33809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The performance stock units granted to the reporting person on January 28, 2019 vested and settled for shares of the Company's common stock."}],"balance_after":226178,"source":{"system":"sec-edgar","filing":"0001415889-19-000253","document":"form4-03052019_040328.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919000253/form4-03052019_040328.xml","form_type":"4"}},{"id":3672951,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Restricted Stock Unit","published_at":"2019-02-06T16:05:14.000Z","date":"2019-02-04","kind":"grant","acquired":true,"shares":18800,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units will vest in three equal annual installments, beginning on February 4, 2020.  Vested shares will be delivered to the reporting person promptly after the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units will vest in three equal annual installments, beginning on February 4, 2020.  Vested shares will be delivered to the reporting person promptly after the vesting date."}],"balance_after":18800,"derivative":{"underlying":"Common Stock","underlying_shares":18800},"source":{"system":"sec-edgar","filing":"0001415889-19-000133","document":"form4-02062019_040201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919000133/form4-02062019_040201.xml","form_type":"4"}},{"id":3682963,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Performance Stock Unit","published_at":"2019-01-30T16:05:17.000Z","date":"2019-01-28","kind":"grant","acquired":true,"shares":33809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan and will vest on March 1, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan and will vest on March 1, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan and will vest on March 1, 2019."}],"balance_after":33809,"derivative":{"underlying":"Common Stock","underlying_shares":33809},"source":{"system":"sec-edgar","filing":"0001415889-19-000106","document":"form4-01302019_040102.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919000106/form4-01302019_040102.xml","form_type":"4"}},{"id":3728054,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Restricted Stock Unit","published_at":"2018-12-18T18:25:14.000Z","date":"2018-12-16","kind":"exercise","acquired":false,"shares":8929,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8929},"source":{"system":"sec-edgar","filing":"0001415889-18-001769","document":"form4-12182018_031258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918001769/form4-12182018_031258.xml","form_type":"4"}},{"id":3728053,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Common Stock","published_at":"2018-12-18T18:25:14.000Z","date":"2018-12-16","kind":"tax_withholding","acquired":false,"shares":3876,"price":68.2,"value":264343.2,"ownership":{"direct":true},"balance_after":192369,"source":{"system":"sec-edgar","filing":"0001415889-18-001769","document":"form4-12182018_031258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918001769/form4-12182018_031258.xml","form_type":"4"}},{"id":3728052,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Common Stock","published_at":"2018-12-18T18:25:14.000Z","date":"2018-12-16","kind":"exercise","acquired":true,"shares":8929,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."}],"balance_after":196245,"source":{"system":"sec-edgar","filing":"0001415889-18-001769","document":"form4-12182018_031258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918001769/form4-12182018_031258.xml","form_type":"4"}},{"id":3780010,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2018-10-31T16:00:17.000Z","date":"2018-10-29","kind":"grant","acquired":true,"shares":59234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was issued pursuant to the Company's 2017 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option is immediately exercisable and will vest in four equal annual installments commencing on October 29, 2019."}],"balance_after":59234,"derivative":{"exercise_price":71.43,"expiration_date":"2028-10-29","underlying":"Common Stock","underlying_shares":59234},"source":{"system":"sec-edgar","filing":"0001415889-18-001565","document":"form4-10312018_041001.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918001565/form4-10312018_041001.xml","form_type":"4"}},{"id":3857271,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (right to buy)","published_at":"2018-08-01T16:05:46.000Z","date":"2018-07-30","kind":"grant","acquired":true,"shares":59234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was issued pursuant to the Company's 2017 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option is immediately exercisable and will vest in four equal annual installments commencing on July 30, 2019."}],"balance_after":59234,"derivative":{"exercise_price":88.91,"expiration_date":"2028-07-30","underlying":"Common Stock","underlying_shares":59234},"source":{"system":"sec-edgar","filing":"0001415889-18-001205","document":"form4-08012018_040824.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918001205/form4-08012018_040824.xml","form_type":"4"}},{"id":3929587,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Restricted Stock Unit","published_at":"2018-05-17T16:08:31.000Z","date":"2018-05-08","kind":"grant","acquired":true,"shares":30079,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units will fully vest on May 8, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units will fully vest on May 8, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date."}],"balance_after":30079,"derivative":{"underlying":"Common Stock","underlying_shares":30079},"source":{"system":"sec-edgar","filing":"0001415889-18-000763","document":"form4-05172018_010518.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918000763/form4-05172018_010518.xml","form_type":"4"}},{"id":3929586,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-17T16:08:31.000Z","date":"2018-05-08","kind":"grant","acquired":true,"shares":59234,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was issued pursuant to the Company's 2017 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option is immediately exercisable and will vest in four equal installments, commencing on May 8, 2019."}],"balance_after":59234,"derivative":{"exercise_price":83.13,"expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":59234},"source":{"system":"sec-edgar","filing":"0001415889-18-000763","document":"form4-05172018_010518.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918000763/form4-05172018_010518.xml","form_type":"4"}},{"id":3929585,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Common Stock","published_at":"2018-05-17T16:08:31.000Z","date":"2018-05-09","kind":"purchase","acquired":true,"shares":1208,"price":82.603,"value":99784.424,"ownership":{"direct":true},"balance_after":187316,"source":{"system":"sec-edgar","filing":"0001415889-18-000763","document":"form4-05172018_010518.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918000763/form4-05172018_010518.xml","form_type":"4"}},{"id":3943435,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Restricted Stock Unit","published_at":"2018-05-08T16:30:32.000Z","date":"2018-05-04","kind":"exercise","acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001415889-18-000695","document":"form4-05082018_010518.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918000695/form4-05082018_010518.xml","form_type":"4"}},{"id":3943434,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Common Stock","published_at":"2018-05-08T16:30:32.000Z","date":"2018-05-04","kind":"tax_withholding","acquired":false,"shares":1519,"price":86.89,"value":131985.91,"ownership":{"direct":true},"balance_after":186108,"source":{"system":"sec-edgar","filing":"0001415889-18-000695","document":"form4-05082018_010518.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918000695/form4-05082018_010518.xml","form_type":"4"}},{"id":3943433,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CHAIRMAN OF BOARD"}}],"security":"Common Stock","published_at":"2018-05-08T16:30:32.000Z","date":"2018-05-04","kind":"exercise","acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock."}],"balance_after":187627,"source":{"system":"sec-edgar","filing":"0001415889-18-000695","document":"form4-05082018_010518.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918000695/form4-05082018_010518.xml","form_type":"4"}},{"id":4049717,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Performance Stock Unit","published_at":"2018-02-20T17:00:52.000Z","date":"2018-02-17","kind":"exercise","acquired":false,"shares":7283,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7283},"source":{"system":"sec-edgar","filing":"0001209191-18-011401","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919118011401/doc4.xml","form_type":"4"}},{"id":4049716,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-02-20T17:00:52.000Z","date":"2018-02-17","kind":"tax_withholding","acquired":false,"shares":2060,"price":95.26,"value":196235.6,"ownership":{"direct":true},"balance_after":184127,"source":{"system":"sec-edgar","filing":"0001209191-18-011401","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919118011401/doc4.xml","form_type":"4"}},{"id":4049715,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-02-20T17:00:52.000Z","date":"2018-02-17","kind":"exercise","acquired":true,"shares":7283,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock."}],"balance_after":186187,"source":{"system":"sec-edgar","filing":"0001209191-18-011401","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919118011401/doc4.xml","form_type":"4"}},{"id":4056141,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Performance Stock Unit","published_at":"2018-02-15T16:06:25.000Z","date":"2018-02-13","kind":"grant","acquired":true,"shares":7283,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan and will vest on February 17, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan and will vest on February 17, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan and will vest on February 17, 2018."}],"balance_after":7283,"derivative":{"underlying":"Common Stock","underlying_shares":7283},"source":{"system":"sec-edgar","filing":"0001209191-18-010348","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919118010348/doc4.xml","form_type":"4"}},{"id":4071252,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-02-08T16:47:29.000Z","date":"2018-02-08","kind":"purchase","acquired":true,"shares":3260,"price":91.9,"value":299594.0,"ownership":{"direct":true},"balance_after":178904,"source":{"system":"sec-edgar","filing":"0001209191-18-008456","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919118008456/doc4.xml","form_type":"4"}},{"id":4084024,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2018-01-31T16:34:43.000Z","date":"2018-01-29","kind":"grant","acquired":true,"shares":33881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was issued pursuant to the Company's 2017 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option is immediately exercisable and will vest as follows: 8,470 shares on January 29, 2019; 8,470 shares on January 29, 2020; 8,470 shares on January 29, 2021; and 8,471 shares on January 29, 2022."}],"balance_after":33881,"derivative":{"exercise_price":103.26,"expiration_date":"2028-01-29","underlying":"Common Stock","underlying_shares":33881},"source":{"system":"sec-edgar","filing":"0001209191-18-006220","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919118006220/doc4.xml","form_type":"4"}},{"id":4125524,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Unit","published_at":"2017-12-20T16:02:54.000Z","date":"2017-12-19","kind":"exercise","acquired":false,"shares":4550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All of the restricted stock units granted to the reporting person on December 19, 2014 vested and settled for shares of the Company's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The restricted stock units were issued pursuant to The Celgene Corporation 2017 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the restricted stock units granted to the reporting person on December 19, 2014 vested and settled for shares of the Company's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4550},"source":{"system":"sec-edgar","filing":"0001209191-17-066617","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117066617/doc4.xml","form_type":"4"}},{"id":4125523,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2017-12-20T16:02:54.000Z","date":"2017-12-19","kind":"tax_withholding","acquired":false,"shares":2094,"price":107.06,"value":224183.64,"ownership":{"direct":true},"balance_after":175644,"source":{"system":"sec-edgar","filing":"0001209191-17-066617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117066617/doc4.xml","form_type":"4"}},{"id":4125522,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2017-12-20T16:02:54.000Z","date":"2017-12-19","kind":"exercise","acquired":true,"shares":4550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All of the restricted stock units granted to the reporting person on December 19, 2014 vested and settled for shares of the Company's common stock."}],"balance_after":177738,"source":{"system":"sec-edgar","filing":"0001209191-17-066617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117066617/doc4.xml","form_type":"4"}},{"id":4177897,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2017-10-31T16:08:45.000Z","date":"2017-10-30","kind":"grant","acquired":true,"shares":33881,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was issued pursuant to the Company's 2017 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option is immediately exercisable and will vest in four equal annual installments, commencing on October 30, 2018."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The option was issued pursuant to the Company's 2017 Stock Incentive Plan."}],"balance_after":33881,"derivative":{"exercise_price":100.97,"expiration_date":"2027-10-30","underlying":"Common Stock","underlying_shares":33881},"source":{"system":"sec-edgar","filing":"0001209191-17-058427","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117058427/doc4.xml","form_type":"4"}},{"id":4247870,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2017-08-01T16:48:36.000Z","date":"2017-07-31","kind":"grant","acquired":true,"shares":33881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The option was issued pursuant to the Company's 2017 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option is immediately exercisable and will vest in four equal annual installments commencing on July 31, 2018."}],"balance_after":33881,"derivative":{"exercise_price":135.41,"expiration_date":"2027-07-31","underlying":"Common Stock","underlying_shares":33881},"source":{"system":"sec-edgar","filing":"0001209191-17-046928","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117046928/doc4.xml","form_type":"4"}},{"id":4247869,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Unit","published_at":"2017-08-01T16:48:36.000Z","date":"2017-07-28","kind":"exercise","acquired":false,"shares":4200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4200},"source":{"system":"sec-edgar","filing":"0001209191-17-046928","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117046928/doc4.xml","form_type":"4"}},{"id":4247868,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2017-08-01T16:48:36.000Z","date":"2017-07-28","kind":"tax_withholding","acquired":false,"shares":1932,"price":134.1,"value":259081.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This amount reflects shares withheld by the Company for the payment of taxes on the vested shares."}],"balance_after":173188,"source":{"system":"sec-edgar","filing":"0001209191-17-046928","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117046928/doc4.xml","form_type":"4"}},{"id":4247867,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2017-08-01T16:48:36.000Z","date":"2017-07-28","kind":"exercise","acquired":true,"shares":4200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock."}],"balance_after":175120,"source":{"system":"sec-edgar","filing":"0001209191-17-046928","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117046928/doc4.xml","form_type":"4"}},{"id":4339030,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Unit","published_at":"2017-05-02T16:18:32.000Z","date":"2017-05-01","kind":"grant","acquired":true,"shares":17131,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on May 1, 2020.  Vested shares will be delivered to the reporting person on the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on May 1, 2020.  Vested shares will be delivered to the reporting person on the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on May 1, 2020.  Vested shares will be delivered to the reporting person on the vesting date."}],"balance_after":17131,"derivative":{"underlying":"Common Stock","underlying_shares":17131},"source":{"system":"sec-edgar","filing":"0001209191-17-029185","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117029185/doc4.xml","form_type":"4"}},{"id":4339029,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2017-05-02T16:18:32.000Z","date":"2017-05-01","kind":"grant","acquired":true,"shares":33880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option is immediately exercisable and will vest in four equal annual installments commencing on May 1, 2018."}],"balance_after":33880,"derivative":{"exercise_price":124.06,"expiration_date":"2027-05-01","underlying":"Common Stock","underlying_shares":33880},"source":{"system":"sec-edgar","filing":"0001209191-17-029185","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117029185/doc4.xml","form_type":"4"}},{"id":4444055,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2017-02-16T17:07:32.000Z","date":"2017-02-14","kind":"tax_withholding","acquired":false,"shares":6643,"price":117.02,"value":777363.86,"ownership":{"direct":true},"balance_after":170920,"source":{"system":"sec-edgar","filing":"0001209191-17-011555","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117011555/doc4.xml","form_type":"4"}},{"id":4444054,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2017-02-16T17:07:32.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":14447,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock relating to the 2014-2016 Long Term Incentive Plan and issued under the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015)."}],"balance_after":177563,"source":{"system":"sec-edgar","filing":"0001209191-17-011555","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117011555/doc4.xml","form_type":"4"}},{"id":4476100,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2017-01-31T16:19:29.000Z","date":"2017-01-30","kind":"grant","acquired":true,"shares":29669,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option is immediately exercisable and will vest in four equal annual installments commencing on January 30, 2018."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015)."}],"balance_after":29669,"derivative":{"exercise_price":113.18,"expiration_date":"2027-01-30","underlying":"Common Stock","underlying_shares":29669},"source":{"system":"sec-edgar","filing":"0001209191-17-006355","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117006355/doc4.xml","form_type":"4"}},{"id":4532163,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":109594,"kind":"person","name":"Alles Mark J","position":1,"cik":"0001538897","reported_name":"Alles Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Unit","published_at":"2016-12-06T16:03:49.000Z","date":"2016-12-02","kind":"exercise","acquired":false,"shares":6560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All of the restricted stock units granted to the reporting person on December 2, 2013 vested and settled for shares of the Company's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The restricted stock units were issued pursuant to The Celgene Corporation 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the restricted stock units granted to the reporting person on December 2, 2013 vested and settled for shares of the Company's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6560},"source":{"system":"sec-edgar","filing":"0001209191-16-153641","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919116153641/doc4.xml","form_type":"4"}}],"next_cursor":"2016-12-06T16:03:49.000000Z,4532163"}